30 closest matches · ranked by relevance
Colorectal Cancer
Primary: Major Morbidity Related to the Intact Primary Tumor — 16.3 probability of major morbidity (%)
Colon Adenocarcinoma · Stage IIA Colon Cancer AJCC v7 · Stage IIB Colon Cancer AJCC v7
Primary: Disease-free Survival — 75.5; 77.4 percentage of patients
Rectal Cancer · Cancer of the Rectum · Colorectal Cancer
Primary: Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment…
Colorectal Neoplasms · Peritoneal Neoplasms
Primary: Peritoneal Recurrence Free Survival at 18 Months — 79; 80 participants
Colorectal Cancer
Primary: Disease-free Survival in Stage III Cancer Patients - Time to Event — NA; NA; NA months — p=0.2024
Colon Cancer · Neoadjuvant Therapy
Primary: Tumor Regression Rate of MSS/pMMR Patients — 7 Participants
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Signet Ring Adenocarcinoma of the Colon
Primary: Proportion of Patients Alive and Progression-free at 15 Months — .482 proportion of participants
Adenocarcinoma of the Colon · Stage III Colon Cancer
Primary: Disease-free Survival (Arms A and D: Wild-type KRAS Patients) — 74.6; 71.5 percentage of participants
Colorectal Cancer
Primary: Percentage of Participants in Objective Response (Partial or Complete Responses) — 47.5 percentage of participants
Colorectal Cancer
Primary: Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor — 48.7; 61.0; 33.3; 51.2 percentage of participants — p=0.2707
Colorectal Cancer
Primary: Objective Response Rate (ORR) in the Intent-to-treat (ITT) Analysis Set — 54.5 percentage of participants
Adenocarcinoma of the Rectum · Mucinous Adenocarcinoma of the Colon · Recurrent Colon Cancer
Primary: Severe Adverse Event (SAE) Rate — 2; 2 participants
Colorectal Cancer
Primary: Progression-free Survival — 2.0; 4.3 months — p=0.001
Metastatic Colorectal Cancer
Primary: Recommended Phase II Dose (RPTD) for the Capecitabine and Aflibercept Doublet Combination — 850 mg/m2
Colon Cancer · Rectal Cancer
Primary: Participants Exhibiting Immune Response — 11 Participants
Colorectal Adenocarcinoma · RAS Wild Type · Stage IV Colorectal Cancer AJCC v7
Primary: Progression-Free Survival (PFS) — 9.7; 5.5 months — p=0.7609
Colorectal Cancer
Primary: Percentage of Participants With Adverse Events — 100 percentage of participants
Colorectal Cancer
Primary: Percentage of Participants Achieving Complete Resection (R0 Resection) — 30.0 percentage of participants
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Adverse Events (AEs) — 100.00; 40.6; 21.1; 9.1 Percentage of participants
Colorectal Cancer
Primary: Durable Clinical Benefit — 3; 32 Participants
Colorectal Neoplasms
Primary: Association Between Neutrophil to Lymphocyte Ratio (NLR) [NLR ≤5 Versus NLR >5] and Progression-Free Survival (PFS) as Assessed by Hazard Ratio — 1.4 hazard ratio…
Colorectal Cancer
Primary: Median Progression-free Survival (PFS) — 12.8 Months
Operation Finding · Complications · Pathology
Primary: Histopathological Outcomes Obtained Through the Surgeries — 20.3; 19.2 nodes
Colorectal Cancer
Primary: Response Rate (Percentage of Participants With Partial or Complete Response) — 43 percentage of participants with response
Small Bowel Cancers · Colorectal Cancers
Primary: Objective Response Rate (ORR) for Triple Therapy — 0; 0 Proportion of participants
Colorectal Cancer
Primary: Percentage of Participants With Disease Progression or Death — 86.14; 90.20; 88.35 percentage of participants
Colorectal Cancer
Primary: Overall Response Rate (ORR) — 75 percentage of evaluable participants
Metastatic Colorectal Cancer
Primary: The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or…
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Objective Tumor Response (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 1 participants
Colorectal Cancer
Primary: Percentage of Participants Achieving Overall Disease Control (ODC) — 87 percentage of participants